Loading stock data…
$3.02-0.05 (-1.63%)
EyePoint, Inc.
EyePoint, Inc. in the Healthcare sector is trading at $3.02 with a market capitalization of $253M. Wall Street consensus targets $25.91 (11 analysts), implying a +757.9% move over the next 12 months. The stock is currently near its 52-week low of $2.97, remaining 74.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $507,000↓ | $696,000↑ | $620,000↓ | $966,000↓ | $5.33M |
| Gross Profit | $507,000↑ | $168,000↓ | $245,000 | $245,000↓ | $5.17M |
| Operating Income | -$97.38M↓ | -$87.23M↓ | -$70.34M↓ | -$62.02M↑ | -$62.23M |
| Net Income | -$94.47M↓ | -$84.83M↓ | -$67.61M↓ | -$59.73M↓ | -$59.43M |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug de...